MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect
- Icahn School of Medicine at Mount Sinai, United States
- Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, United States
- Sanford Burnham Prebys Medical Discovery Institute, United States
- New York University Abu Dhabi, United Arab Emirates
Abstract
Rapid cellular proliferation in early development and cancer depends on glucose metabolism to fuel macromolecule biosynthesis. Metabolic enzymes are presumed regulators of this glycolysis-driven metabolic program, known as the Warburg effect, however few have been identified. We uncover a previously unappreciated role for Mannose phosphate isomerase (MPI) as a metabolic enzyme required to maintain Warburg metabolism in zebrafish embryos and in both primary and malignant mammalian cells. The functional consequences of MPI loss are striking: glycolysis is blocked and cells die. These phenotypes are caused by induction of p53 and accumulation of the glycolytic intermediate Fructose 6-Phosphate, leading to engagement of the hexosamine biosynthetic pathway (HBP), increased O-GlcNAcylation, and p53 stabilization. Inhibiting the HBP through genetic and chemical methods reverses p53 stabilization and rescues the Mpi-deficient phenotype. This work provides mechanistic evidence by which MPI loss induces p53, and identifies MPI as a novel regulator of p53 and Warburg metabolism.
Data availability
-
Transcriptome profiles of surgically resected HCC tumor tissuesPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE10186).
Article and author information
Author details
Funding
National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK101340)
- Jaime Chu
The Mindich Child Health and Development Institute at Mount Sinai
- Jaime Chu
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080789)
- Kirsten C Sadler
National Institute on Alcohol Abuse and Alcoholism (R01AA018886)
- Kirsten C Sadler
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK99551)
- Hudson H Freeze
The Rocket Fund
- Hudson H Freeze
National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007792)
- Charles DeRossi
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Ralph DeBerardinis, UT Southwestern Medical Center, United States
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#IACUC-2015-0050) of the Icahn School of Medicine at Mount Sinai.
Version history
- Received: October 19, 2016
- Accepted: June 22, 2017
- Accepted Manuscript published: June 23, 2017 (version 1)
- Version of Record published: July 3, 2017 (version 2)
Copyright
© 2017, DeRossi et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,913
- views
-
- 555
- downloads
-
- 25
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect
eLife 6:e22477.
https://doi.org/10.7554/eLife.22477
Further reading
-
- Cancer Biology
- Cell Biology
High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.
-
- Cancer Biology
- Cell Biology
Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.
